B. Metzler seel. Sohn & Co. AG Purchases 14,572 Shares of GE HealthCare Technologies Inc. $GEHC

Key Points

• B. Metzler seel. Sohn & Co. AG increased its stake in GE HealthCare by 25%, buying 14,572 shares to own 72,783 shares worth about $5.97 million at the end of the quarter.
• Analysts are mixed but cautious: the consensus rating is Hold with a $89.77 price target (8 Buy, 6 Hold, 1 Sell).
• GE HealthCare beat quarterly estimates with EPS of $1.44 and revenue of $5.70B (up 7.1% YoY) and announced a quarterly dividend of $0.035 per share (annualized $0.14, yield 0.2%).

B. Metzler seel. Sohn & Co. AG lifted its position in GE HealthCare Technologies Inc. (NASDAQ:GEHC - Free Report) by 25.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 72,783 shares of the company's stock after purchasing an additional 14,572 shares during the quarter. B. Metzler seel. Sohn & Co. AG's holdings in GE HealthCare Technologies were worth $5,970,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in GEHC. E Fund Management Hong Kong Co. Ltd. increased its holdings in shares of GE HealthCare Technologies by 130.7% in the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 346 shares of the company's stock worth $26,000 after purchasing an additional 196 shares during the last quarter. Godsey & Gibb Inc. bought a new stake in shares of GE HealthCare Technologies in the third quarter worth about $26,000. Optima Capital LLC bought a new stake in shares of GE HealthCare Technologies in the fourth quarter worth about $27,000. Maseco LLP bought a new stake in shares of GE HealthCare Technologies in the fourth quarter worth about $29,000. Finally, Oakworth Capital Inc. increased its holdings in shares of GE HealthCare Technologies by 1,876.2% in the third quarter. Oakworth Capital Inc. now owns 415 shares of the company's stock worth $31,000 after purchasing an additional 394 shares during the last quarter. 82.06% of the stock is owned by institutional investors.

Analyst Ratings Changes

GEHC has been the topic of several research reports. Wall Street Zen cut GE HealthCare Technologies from a "buy" rating to a "hold" rating in a report on Saturday, March 21st. Piper Sandler reduced their target price on GE HealthCare Technologies from $96.00 to $88.00 and set an "overweight" rating on the stock in a report on Friday, April 17th. Morgan Stanley lifted their target price on GE HealthCare Technologies from $80.00 to $85.00 and gave the stock an "equal weight" rating in a report on Wednesday, February 4th. Mizuho reduced their price objective on GE HealthCare Technologies from $95.00 to $90.00 and set an "outperform" rating on the stock in a research note on Monday, April 13th. Finally, UBS Group cut GE HealthCare Technologies from a "neutral" rating to a "sell" rating and boosted their price objective for the stock from $73.00 to $77.00 in a research note on Thursday, January 15th. Eight equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $89.77.

GE HealthCare Technologies Trading Down 2.1%

Shares of NASDAQ GEHC opened at $69.89 on Friday. The business's 50 day moving average is $74.88 and its two-hundred day moving average is $77.82. The company has a debt-to-equity ratio of 0.91, a current ratio of 1.37 and a quick ratio of 1.13. GE HealthCare Technologies Inc. has a 1-year low of $64.77 and a 1-year high of $89.77. The stock has a market capitalization of $31.89 billion, a P/E ratio of 15.33, a PEG ratio of 1.57 and a beta of 1.17.

GE HealthCare Technologies (NASDAQ:GEHC - Get Free Report) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $1.44 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.04. The company had revenue of $5.70 billion for the quarter, compared to analysts' expectations of $5.60 billion. GE HealthCare Technologies had a return on equity of 21.35% and a net margin of 10.11%.The firm's revenue for the quarter was up 7.1% on a year-over-year basis. During the same period in the previous year, the firm posted $1.45 earnings per share. GE HealthCare Technologies has set its FY 2026 guidance at 4.950-5.150 EPS. As a group, research analysts expect that GE HealthCare Technologies Inc. will post 5 EPS for the current year.

GE HealthCare Technologies Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Friday, April 3rd will be paid a dividend of $0.035 per share. The ex-dividend date of this dividend is Thursday, April 2nd. This represents a $0.14 dividend on an annualized basis and a dividend yield of 0.2%. GE HealthCare Technologies's dividend payout ratio is currently 3.07%.

GE HealthCare Technologies Company Profile

GE HealthCare Technologies NASDAQ: GEHC is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.

In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime.

Want to see what other hedge funds are holding GEHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GE HealthCare Technologies Inc. (NASDAQ:GEHC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.